Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
The present invention relates to solid state forms of a p-toluenesulfonic acid salt (PTSA) of the selective PI3K delta inhibitor (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one (TGR-1202). The present invention also relates to methods of preparing the same, pharmaceutical compositions containing them, and methods of treating a PI3K kinase mediated disease or disorder, such as cancer, by administering the same.
1. A method for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, peripheral T-cell lymphoma, or Hodgkin's lymphoma comprising the step of administering to a subject in need thereof an effective amount of a p-toluenesulfonic acid salt of the compound
wherein the salt has a d(0.9) of from about 5 to about 50 μm.
2. A method for treating non-Hodgkin's lymphoma in a subject in need thereof comprising the step of administering to the subject an effective amount of a p-toluenesulfonic acid salt of the compound
wherein the salt has a d(0.9) of from about 5 to about 50 μm.
3. A method for treating chronic lymphocytic leukemia in a subject in need thereof comprising the step of administering to the subject an effective amount of a p-toluenesulfonic acid salt of the compound
wherein the salt has a d(0.9) of from about 5 to about 50 μm.
4. A method for treating follicular lymphoma in a subject in need thereof comprising the step of administering to the subject an effective amount of a p-toluenesulfonic acid salt of the compound
wherein the salt has a d(0.9) of from about 5 to about 50 μm.
5. The method of claim 1 , wherein the salt has a d(0.9) of from about 5 to about 25 μm.
6. The method of claim 2 , wherein the salt has a d(0.9) of from about 5 to about 25 μm.
7. The method of claim 3 , wherein the salt has a d(0.9) of from about 5 to about 25 μm.
8. The method of claim 4 , wherein the salt has a d(0.9) of from about 5 to about 25 μm.
9. The method of claim 1 , wherein the salt has a d(0.9) of from about 5 to about 15 μm.
10. The method of claim 2 , wherein the salt has a d(0.9) of from about 5 to about 15 μm.
11. The method of claim 3 , wherein the salt has a d(0.9) of from about 5 to about 15 μm.
12. The method of claim 4 , wherein the salt has a d(0.9) of from about 5 to about 15 μm.
13. The method of claim 1 , wherein the salt has a d(0.5) of from about 1 to about 10 μm.
14. The method of claim 2 , wherein the salt has a d(0.5) of from about 1 to about 10 μm.
15. The method of claim 3 , wherein the salt has a d(0.5) of from about 1 to about 10 μm.
16. The method of claim 4 , wherein the salt has a d(0.5) of from about 1 to about 10 μm.
17. The method of claim 1 , wherein the salt has a d(0.5) of from about 2 to about 5 μm.
18. The method of claim 2 , wherein the salt has a d(0.5) of from about 2 to about 5 μm.
19. The method of claim 3 , wherein the salt has a d(0.5) of from about 2 to about 5 μm.
20. The method of claim 4 , wherein the salt has a d(0.5) of from about 2 to about 5 μm.
21. The method of claim 1 , wherein the salt exhibits a XRPD pattern having one or more peaks selected from 5.0, 10.1, 22.1, and 24.5±0.2° 2Θ.
22. The method of claim 2 , wherein the salt exhibits a XRPD pattern having one or more peaks selected from 5.0, 10.1, 22.1, and 24.5±0.2° 2Θ.
23. The method of claim 3 , wherein the salt exhibits a XRPD pattern having one or more peaks selected from 5.0, 10.1, 22.1, and 24.5±0.2° 2Θ.
24. The method of claim 4 , wherein the salt exhibits a XRPD pattern having one or more peaks selected from 5.0, 10.1, 22.1, and 24.5±0.2° 2Θ.
25. The method of claim 1 , wherein the ratio of p-toluenesulfonic acid to the compound
is about 1:1.
26. The method of claim 2 , wherein the ratio of p-toluenesulfonic acid to the compound
is about 1:1.
27. The method of claim 3 , wherein the ratio of p-toluenesulfonic acid to the compound
is about 1:1.
28. The method of claim 4 , wherein the ratio of p-toluenesulfonic acid to the compound
is about 1:1.
29. A method for the treatment of indolent non-Hodgkin's lymphoma comprising the step of administering to a subject in need thereof an effective amount of a p-toluenesulfonic acid salt of the compound
wherein the salt has a d(0.9) of from about 5 to about 50 μm.
30. The method of claim 29 , wherein the salt has a d(0.9) of from about 5 to about 25 μm.
31. The method of claim 29 , wherein the salt has a d(0.9) of from about 5 to about 15 μm.
32. The method of claim 29 , wherein the salt has a d(0.5) of from about 1 to about 10 μm.
33. The method of claim 29 , wherein the salt has a d(0.5) of from about 2 to about 5 μm.
34. The method of claim 29 , wherein the salt exhibits a XRPD pattern having one or more peaks selected from 5.0, 10.1, 22.1, and 24.5±0.2° 2Θ.
35. The method of claim 29 , wherein the ratio of p-toluenesulfonic acid to the compound
is about 1:1.
36. The method of claim 1 , wherein the salt is administered orally.
37. The method of claim 2 , wherein the salt is administered orally.
38. The method of claim 3 , wherein the salt is administered orally.
39. The method of claim 4 , wherein the salt is administered orally.
40. The method of claim 29 , wherein the salt is administered orally.